Journal: Journal of Cellular Physiology
Article Title: The long noncoding RNA NORAD enhances the TGF‐β pathway to promote hepatocellular carcinoma progression by targeting miR‐202‐5p
doi: 10.1002/jcp.27869
Figure Lengend Snippet: miR‐202‐5p, targeted by NORAD, inhibit TGFBR1 and TGFBR2 in hepatocellular carcinoma (HCC) cell lines. (a) Targets prediction of NORAD and miR‐202‐5p. (b,c) miR‐202‐5p mimic and its control were added in HCC cells which were transfected by wild‐type or mutated NORAD, TGFBR1 3′‐UTR and TGFBR2 3′‐UTR. The histogram indicates the luciferase values measured 48 hr after transfection. (d) NORAD knockdown, miR‐202‐5p inhibitor and their controls were added in HCC cells which contained TGFBR1 3′‐UTR and TGFBR2 3′‐UTR. The histogram indicates the luciferase values measured 48 hr after transfection. (e) Messenger RNA levels of TGFBR1 and TGFBR2 were measured after NORAD knockdown, miR‐202‐5p inhibitor and their controls were added. (f) Phosphorylation level of Smad2/3 were tested by western blot analysis. *Statistical significance, p < 0.05; **Statistical significance, p < 0.01. TGFBR: transforming growth factor β receptors; UTR: untranslated region [Color figure can be viewed at wileyonlinelibrary.com]
Article Snippet: Antibody used were listed below: anti‐phospho‐Smad2/Smad3 (p‐smad2/3; bs‐8853R; Bioss, Beijing, China), anti‐Smad2/3 (8685s; Cell Signaling Technology, Danvers, MA), anti‐GAPDH (10494‐1‐AP; Proteintech, Wuhan, China).
Techniques: Transfection, Luciferase, Western Blot